4
On Monday, Pliant Therapeutics Inc. (NASDAQ:PLRX) announced that it would discontinue the BEACON-IPF Phase 2b trial, which evaluated bexotegrast in patients with idiopathic pulmonary fibrosis (IPF).
The move follows a prespecified data review and recommendation by the trial’s independent Data Safety Monitoring Board (DSMB) and a secondary review and recommendation by an outside expert panel.
While an imbalance in unadjudicated IPF-related adverse events between the treatment and placebo groups led to the discontinuation of the trial, early evidence of efficacy on the forced vital capacity (FVC) endpoint was also observed.
Also Read: Pliant Therapeutics Pauses …
